Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HUMATIN vs AKTOB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and production of nonfunctional proteins.
Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.
Hepatic coma (adjunctive therapy to reduce ammonia-forming bacteria in the gut),Diarrhea caused by enteropathogenic bacteria (e.g., Shigella, E. coli, Salmonella, Proteus, Staphylococcus, Pseudomonas aeruginosa)
Prevention of organ rejection in kidney, liver, and heart transplants,Rheumatoid arthritis,Psoriasis
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
Adults: 10 mg orally once daily.
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Terminal elimination half-life is 8-12 hours; prolonged in renal impairment (up to 20-30 hours in anuria).
Minimally absorbed from the gastrointestinal tract; systemically absorbed drug undergoes minimal hepatic metabolism.
Hepatic via CYP3A4 enzyme system; major metabolites include AM1, AM9, and AM4N.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Renal: 70-80% unchanged; biliary/fecal: 10-15% as metabolites.
0% (negligible binding due to high polarity and minimal absorption)
20-30% primarily to albumin.
0.2 L/kg (reflects limited distribution to extracellular fluid in absorbed fraction; primarily confined to GI tract)
0.25-0.4 L/kg; indicates distribution primarily in extracellular fluid.
Oral: ~1% (ranges 0.5-1.5% due to poor absorption from gastrointestinal tract)
Intramuscular: approximately 90%; oral: not absorbed (0% due to degradation in GI tract).
Reduce dose and/or extend interval based on Cr Cl: Cr Cl 50-90 m L/min: 60-90% of dose; Cr Cl 10-50 m L/min: 30-60% of dose; Cr Cl <10 m L/min: 20-30% of dose.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 5 mg once daily; GFR <15 m L/min or dialysis: 2.5 mg once daily.
No specific Child-Pugh based adjustments; caution in severe hepatic impairment due to potential nephrotoxicity.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
For hepatic coma: 15-25 mg/kg/day orally in 4 divided doses; for infectious diarrhea: 50 mg/kg/day orally in 4 divided doses, max 4 g/day.
Not established for children <18 years.
Adjust based on renal function; monitor for nephrotoxicity and ototoxicity; consider lower initial doses due to age-related renal decline.
No specific dose adjustment; monitor for hypotension and renal function.
No FDA black box warning.
Increased risk of lymphomas and other malignancies, particularly of the skin. Increased susceptibility to infections. Cyclosporine can cause nephrotoxicity and hepatotoxicity.
Ototoxicity (mainly with prolonged use or renal impairment),Nephrotoxicity,Neuromuscular blockade (use caution in patients with myasthenia gravis or receiving neuromuscular blocking agents),Superinfection with resistant organisms,Use in renal impairment may increase risk of toxicity,Not for systemic infections (poor absorption)
Nephrotoxicity, hepatotoxicity, hypertension, hyperkalemia, neurotoxicity, increased risk of infections and malignancies, anaphylaxis (IV formulation).
Hypersensitivity to paromomycin or other aminoglycosides,Intestinal obstruction,Severe ulcerative bowel lesions
Hypersensitivity to cyclosporine or any component of the formulation, abnormal renal function, uncontrolled hypertension, malignancies, concurrent use with PUVA or UVB therapy in psoriasis.
No significant food interactions. Administer with meals to minimize gastrointestinal irritation.
No significant food interactions. Avoid alcohol while taking this medication.
FDA Pregnancy Category D. Humatin (paromomycin) is an aminoglycoside antibiotic. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. However, potential benefits may warrant use in pregnant women despite potential risks. Aminoglycosides can cause fetal harm when administered to a pregnant woman, including ototoxicity and nephrotoxicity. Paromomycin is poorly absorbed after oral administration, so systemic exposure is minimal. Risk is considered low, but caution is advised.
First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; monitor for fetal growth restriction and oligohydramnios.
It is not known whether paromomycin is excreted in human milk after oral administration. Paromomycin is minimally absorbed systemically, so exposure to breastfed infants is expected to be low. However, because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio: Not available.
Not recommended during breastfeeding. M/P ratio unknown; potential infant exposure via milk.
No dose adjustment is required during pregnancy. Paromomycin is poorly absorbed orally, and its pharmacokinetics are not significantly altered in pregnancy. However, caution is advised in patients with renal impairment or inflammatory bowel disease due to potential increased absorption.
No standard dose adjustment; increased clearance in pregnancy may require higher doses; therapeutic drug monitoring advised.
Humatin (paromomycin) is an aminoglycoside antibiotic used primarily for intestinal amebiasis and hepatic coma. For hepatic coma, use as short-term adjunctive therapy; monitor for ototoxicity and nephrotoxicity, especially in renal impairment. Oral absorption is poor, so systemic toxicity is rare except with ulcerative bowel disease. Administer with food to reduce GI upset.
AKTOB is a beta-lactam antibiotic; monitor for hypersensitivity reactions, especially in patients with penicillin allergy. Adjust dose in renal impairment (Cr Cl <30 m L/min). Administer by slow IV infusion over 3-5 minutes or as directed. Observe for signs of Clostridioides difficile infection.
Take this medication exactly as prescribed, with food to lessen stomach upset.,Complete the full course of therapy even if you feel better.,Drink plenty of fluids to maintain hydration.,Report any hearing loss, ringing in ears, dizziness, or changes in urine output immediately.,May cause diarrhea; notify your doctor if severe or persistent.
Complete the full course of therapy even if symptoms improve.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing immediately.,Inform your doctor if you have kidney problems or are on dialysis.,This medication may cause diarrhea; do not treat with anti-diarrheal medications without consulting your doctor.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HUMATIN vs AKTOB, answered by our medical review team.
HUMATIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and production of nonfunctional proteins.. AKTOB is a Aminoglycoside Antibiotic (Ophthalmic) that works by Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HUMATIN and AKTOB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HUMATIN is: 15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.. The standard adult dose of AKTOB is: Adults: 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HUMATIN and AKTOB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HUMATIN is classified as Category C. FDA Pregnancy Category D. Humatin (paromomycin) is an aminoglycoside antibiotic. There is positive evidence of human fetal risk based on adverse reaction data from investigational . AKTOB is classified as Category C. First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.